[HTML][HTML] Autoimmune disorders of the nervous system: pathophysiology, clinical features, and therapy
S Bhagavati - Frontiers in neurology, 2021 - frontiersin.org
Remarkable discoveries over the last two decades have elucidated the autoimmune basis of
several, previously poorly understood, neurological disorders. Autoimmune disorders of the …
several, previously poorly understood, neurological disorders. Autoimmune disorders of the …
Primary central nervous system lymphoma
S Bhagavathi, JD Wilson - Archives of pathology & …, 2008 - meridian.allenpress.com
… Sharathkumar Bhagavathi, Jon D. Wilson; Primary Central Nervous System Lymphoma. Arch
… Recipient(s) will receive an email with a link to 'Primary Central Nervous System Lymphoma…
… Recipient(s) will receive an email with a link to 'Primary Central Nervous System Lymphoma…
Primary bone lymphoma
S Bhagavathi, K Fu - Archives of pathology & laboratory …, 2009 - meridian.allenpress.com
Primary bone lymphomas are rare, even though secondary involvement of the bone marrow
is a common event in systemic lymphomas. Most primary bone lymphomas are primary …
is a common event in systemic lymphomas. Most primary bone lymphomas are primary …
Detection of human T-cell lymphoma/leukemia virus type I DNA and antigen in spinal fluid and blood of patients with chronic progressive myelopathy
S Bhagavati, G Ehrlich, RW Kula, S Kwok… - … England Journal of …, 1988 - Mass Medical Soc
The presence of antibodies to human T-cell lymphoma/leukemia virus Type I (HTLV-I) has
been associated with chronic progressive myelopathy. We attempted to isolate the virus from …
been associated with chronic progressive myelopathy. We attempted to isolate the virus from …
Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma
…, LM Smith, G Wright, S Bhagavathi… - Blood, The Journal …, 2015 - ashpublications.org
… Cell-cycle analysis revealed increased cell proliferation and enhanced G1-S phase … oncogene
homolog-1 activation and G1-S cell cycle transition were downregulated upon ectopic miR…
homolog-1 activation and G1-S cell cycle transition were downregulated upon ectopic miR…
[HTML][HTML] B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas
…, P Lin, XJ Wang, RN Miranda, S Bhagavathi… - Modern pathology, 2015 - Elsevier
Large B-cell lymphomas with IGH@BCL2 and MYC rearrangement, known as double-hit
lymphoma (DHL), are clinically aggressive neoplasms with a poor prognosis. Some large B-cell …
lymphoma (DHL), are clinically aggressive neoplasms with a poor prognosis. Some large B-cell …
MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma
Anaplastic large-cell lymphomas (ALCLs) encompass at least 2 systemic diseases
distinguished by the presence or absence of anaplastic lymphoma kinase (ALK) expression. We …
distinguished by the presence or absence of anaplastic lymphoma kinase (ALK) expression. We …
Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis
…, TC Greiner, JM Vose, S Bhagavathi… - Blood, The Journal …, 2012 - ashpublications.org
miRNA deregulation has been implicated in the pathogenesis of mantle cell lymphoma (MCL).
Using a high-throughput quantitative real-time PCR platform, we performed miRNA …
Using a high-throughput quantitative real-time PCR platform, we performed miRNA …
Isolation and enrichment of skeletal muscle progenitor cells from mouse bone marrow
S Bhagavati, W Xu - Biochemical and biophysical research communications, 2004 - Elsevier
There is great interest in the therapeutic potential of non-hematopoietic stem cells obtained
from bone marrow called mesenchymal stem cells (MSCs). Rare myogenic progenitor cells …
from bone marrow called mesenchymal stem cells (MSCs). Rare myogenic progenitor cells …
ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in “double hit” lymphoma cells
N Johnson-Farley, J Veliz, S Bhagavathi… - Leukemia & …, 2015 - Taylor & Francis
Double hit lymphoma (DHL) is a recently recognized lymphoma with a survival of less than
2 years. Both ABT-737, a Bcl-2/Bcl-XL inhibitor, and ABT-199, which selectively targets Bcl-2, …
2 years. Both ABT-737, a Bcl-2/Bcl-XL inhibitor, and ABT-199, which selectively targets Bcl-2, …